AstraZeneca PLC Appoints Andreas Rummelt as a Non-Executive Director
AstraZeneca PLC announced that the Board has appointed Andreas Rummelt as a Non-Executive Director, following the completion of its acquisition of Alexion Pharmaceuticals Inc. Andreas has more than 20 years’ experience in executive management positions in the pharmaceutical industry. His international career has focused on technical research and development, manufacturing and quality, as well as a period leading a generics business as Chief Executive Officer. He is now Chairman and Managing Partner of InterPharmaLink AG.
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.